NcXHF

ECONOMOPOULOU, BOURHIS, AND PSYRRI
in recurrent/metastatic HNSCC after platinum therapy: LUX-Head and
Neck 1. Presented at: Fifth International Conference on Innovative Approaches
in Head and Neck Oncology; February 2015; Nice, France;
(abstr OC-005).
6. Blanchard P, Lee A, Leclerq J, et al. What is the best treatment in nasopharyngeal
carcinoma? An individual patient data network metaanalysis.
Presented at: Fifth International Conference on Innovative
Approaches in Head and Neck Oncology; February 2015; Nice, France;
(abstr OC-003).
7. Langendijk H, Kaanders JH, Doornaert P, et al. POPART vs CPORT in
squamous cell head and neck cancer: results of a multicenter randomized
study of the Dutch head and neck study group. Presented at: Fifth
International Conference on Innovative Approaches in Head and Neck
Oncology; February 2015; Nice, France; (abstr OC-003).
8. Even C, Breuskin I, Ileana E, et al. Molecular screening for cancer treatment
optimization in head and neck cancer (MOSCATO 01). Presented
at: Fifth International Conference on Innovative Approaches in Head
and Neck Oncology; February 2015; Nice, France; (abstr OC-0074).
9. Pai S, Smith D, Peng S, et al. Therapeutic HPV vaccine increases sensitivity
of poorly immunogenic tumor to anti-PD-1 monotherapy. Presented
at: Fifth International Conference on Innovative Approaches in
Head and Neck Oncology; February 2015; Nice, France; (abstr 0058).
10. O’Sullivan B, Huang S, Waldron J, et al. Refıning UICC TNM stage and
prognostic groups for nonmetastatic HPV-related oropharyngeal carcinomas.
Presented at: Fifth International Conference on Innovative Approaches
in Head and Neck Oncology; February 2015; Nice, France;
(abstr 0081).
11. Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy:
a new systemic therapy for solid tumors? Cancer Immunol Res.
2014;2:831-838.
12. Swanson MS, Sinha UK. Rationale for combined blockade of PD-1 and
CTLA-4 in advanced head and neck squamous cell cancer: review of
current data. Oral Oncol. 2015;51:12-15.
13. Dunne EF, Park IU. HPV and HPV-associated diseases. Infect Dis Clin
North Am. 2013;27:765-778.
14. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance
of oral human papillomavirus infection in men: the HIM cohort
study. Lancet. 2013;382:877-887.
15. Hibma MH. The immune response to papillomavirus during infection
persistence and regression. Open Virol J. 2012;6:241-248.
16. Sun XW, Ellerbrock TV, Lungu O, et al. Human papillomavirus infection
in human immunodefıciency virus-seropositive women. Obstet
Gynecol. 1995;85:680-686.
17. Stanley M, Gissmann L, Nardelli-Haefliger D. Immunobiology of human
papillomavirus infection and vaccination: implications for second
generation vaccines. Vaccine. 2008;26(suppl 10):K62-K67.
18. Psyrri A, DiMaio D. Human papillomavirus in cervical and head-andneck
cancer. Nat Clin Pract Oncol. 2008;5:24-31.
19. D’Souza G, Dempsey A. The role of HPV in head and neck cancer and
review of the HPV vaccine. Prev Med. 2011;53 (suppl 1):S5-S11.
20. Pai SI. Biology and immune therapy of HPV-related oropharyngeal cancer.
Presented at: 2011 American Society of Clinical Oncology Annual
Meeting; June 2011; Chicago, IL.
21. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:
PD-L1 pathway in immune resistance of HPV-associated head and neck
squamous cell carcinoma. Cancer Res. 2013;73:1733-1741.
22. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-deathreceptor-1
treatment with pembrolizumab in ipilimumab-refractory
advanced melanoma: a randomised dose-comparison cohort of a phase
1 trial. Lancet. 2014;384:1109-1117.
23. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 2015;372:320-330.
24. Vasilakopoulou M VV, Rampias T, Sasaki C, et al. Effect of PDL-1 expression
on prognosis in head and neck squamous cell carcinoma. J Clin
Oncol. 2013;31. (suppl; abstr 6012).
25. Psyrri A, Rampias T, Vermorken JB. The current and future impact of
human papillomavirus on treatment of squamous cell carcinoma of the
head and neck. Ann Oncol. 2014;25:2101-2115.
26. Gillison ML, Castellsague X, Chaturvedi A, et al. Eurogin roadmap:
comparative epidemiology of HPV infection and associated cancers of
the head and neck and cervix. Int J Cancer. 2014;134:497-507.
27. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package
time in surgery and postoperative radiation therapy for squamous carcinoma
of the head and neck. Head Neck. 2002;24:115-126.
28. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor
alpha and epidermal growth factor receptor messenger RNA are early
markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;
53:3579-3584.
29. Grandis JR, Tweardy DJ. TGF-alpha and EGFR in head and neck cancer.
J Cell Biochem Suppl. 1993;17F:188-191.
30. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy
plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-
1127.
31. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter
phase II study to evaluate the effıcacy and toxicity of cetuximab as
a single agent in patients with recurrent and/or metastatic squamous cell
carcinoma of the head and neck who failed to respond to platinumbased
therapy. J Clin Oncol. 2007;25:2171-2177.
32. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or
cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma
with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.
33. Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of
afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma
of the head and neck. Ann Oncol. 2014;25:1813-1820.
34. Tsimberidou AM, Wen S, Hong DS, et al. Personalized medicine for
patients with advanced cancer in the phase I program at MD Anderson:
validation and landmark analyses. Clin Cancer Res. 2014;20:
4827-4836.
35. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of
head and neck squamous cell carcinoma. Science. 2011;333:1157-
1160.
36. Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization
of oral squamous cell carcinoma identifıes frequent somatic drivers.
Cancer Discov. 2013;3:770-781.
37. Lui VW, Hedberg ML, Li H, et al. Frequent mutation of the PI3K pathway
in head and neck cancer defınes predictive biomarkers. Cancer Discov.
2013;3:761-769.
38. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of
head and neck squamous cell carcinoma reveals inactivating mutations
in NOTCH1. Science. 2011;333:1154-1157.
39. Tsimberidou AM, Eggermont AM, Schilsky RL, et al. Strategies to overcome
clinical, regulatory, and fınancial challenges in the implementation
of personalized medicine. Am Soc Clin Oncol Educ Book. 2014;34:
61-69.
e328
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook